drugset / Trial / NCT00495339
MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Estimate of clinical and microbiological efficacy of Levofloxacin (Tavanic) in combine therapy of MDR TB. Estimate of safety of Levofloxacin (Tavanic) in combine therapy of MDR TB.
Timeline
- Start
- 2007-06
- Primary completion
- 2008-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levofloxacin | Small molecule | 500 mg | Oral |
| Subject | Levofloxacin | Small molecule | 1000 mg | Oral |